The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
George Fust - One of the best experts on this subject based on the ideXlab platform.
-
long term Danazol prophylaxis does not lead to increased carotid intima media thickness in hereditary angioedema patients
Atherosclerosis, 2008Co-Authors: Robert Szegedi, Gabor Szeplaki, Lilian Varga, Zoltan Prohaszka, Zoltan Szeplaki, Istvan Karadi, George FustAbstract:Abstract Background Hereditary angioedema (HAE) is characterized by episodic edematous attacks due to the deficiency of the C1-inhibitor (C1-INH). Recently, we have described that the long-term use of Danazol affects lipid metabolism, resulting in decreased high-density lipoprotein (HDL) and increased low-density lipoprotein (LDL) cholesterol levels, which might lead to accelerated, early atherosclerosis. Our aim in the present study was to investigate the impact of Danazol treatment on the risk of atherosclerosis in HAE patients. Methods The prevalence of vascular disease, as well as carotid intima-media thickness (IMT) – an objective marker of atherosclerosis – was determined in 32 HAE patients undergoing Danazol prophylaxis, and compared to 25 HAE patients without Danazol treatment, as well as to 20 healthy controls. Distinct atherosclerosis risk profiles were determined in addition. Results HAE patients with Danazol prophylaxis had higher body mass index ( p =0.0055 and 0.0020), creatinine ( p =0.0001 and 0.0130), alanine aminotransferase ( p =0.0298 and 0.0457), LDL ( p =0.0060 and p p =0.5465) carotid IMT values, when comparing patients with or without long-term Danazol prophylaxis. Conclusions Thickening of IMT due to Danazol use was not observed in HAE patients. We hypothesize that the functional deficiency of C1-INH might confer protection against atherosclerosis in these patients.
-
adverse effects of Danazol prophylaxis on the lipid profiles of patients with hereditary angioedema
The Journal of Allergy and Clinical Immunology, 2005Co-Authors: Gabor Szeplaki, Lilian Varga, Istvan Karadi, George Fust, Szilvia Valentin, Monika Kleiber, Laszlo RomicsAbstract:Background Hereditary angioedema (HAE) is a rare disorder caused by the deficiency of the C1-inhibitor gene (C1INH) . Patients experience recurrent bouts of edema, which can occur in almost any region of the body. As regards the treatment of the disease, Danazol (an attenuated androgen) is used, among other agents, for long-term prophylaxis. Objective The aim of this study was to investigate the possible adverse effects of Danazol on serum lipid profile, as well as to ascertain whether Danazol treatment is associated with an increased risk of atherosclerosis. Methods Serum concentrations of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, apolipoprotein A-I, apolipoprotein B-100, and lipoprotein(a) were compared between Danazol-treated patients with HAE and 2 control groups (ie, patients who did not receive long-term Danazol prophylaxis and untreated healthy subjects). Results Serum concentrations of HDL ( P =.0002 and P P =.0015 and P P =.0129 and P =.0127) and apolipoprotein B-100 ( P =.0456 and P =.0013) were higher in the Danazol-treated patients compared with the 2 control groups, respectively. No significant difference was found in total cholesterol, triglyceride, or lipoprotein(a) levels. Patients who received Danazol had an 11.6 (95% CI, 2.7-49.7) times higher risk for abnormally low HDL levels and a 4.4 (95% CI, 1.2-16.0) times lower risk for high LDL concentrations. Conclusions Our findings indicate that the long-term use of Danazol is associated with an increased risk for early atherosclerosis in patients with HAE. Consequently, monitoring of HDL and LDL levels at regular intervals is recommended during follow-up.
Istvan Karadi - One of the best experts on this subject based on the ideXlab platform.
-
long term Danazol prophylaxis does not lead to increased carotid intima media thickness in hereditary angioedema patients
Atherosclerosis, 2008Co-Authors: Robert Szegedi, Gabor Szeplaki, Lilian Varga, Zoltan Prohaszka, Zoltan Szeplaki, Istvan Karadi, George FustAbstract:Abstract Background Hereditary angioedema (HAE) is characterized by episodic edematous attacks due to the deficiency of the C1-inhibitor (C1-INH). Recently, we have described that the long-term use of Danazol affects lipid metabolism, resulting in decreased high-density lipoprotein (HDL) and increased low-density lipoprotein (LDL) cholesterol levels, which might lead to accelerated, early atherosclerosis. Our aim in the present study was to investigate the impact of Danazol treatment on the risk of atherosclerosis in HAE patients. Methods The prevalence of vascular disease, as well as carotid intima-media thickness (IMT) – an objective marker of atherosclerosis – was determined in 32 HAE patients undergoing Danazol prophylaxis, and compared to 25 HAE patients without Danazol treatment, as well as to 20 healthy controls. Distinct atherosclerosis risk profiles were determined in addition. Results HAE patients with Danazol prophylaxis had higher body mass index ( p =0.0055 and 0.0020), creatinine ( p =0.0001 and 0.0130), alanine aminotransferase ( p =0.0298 and 0.0457), LDL ( p =0.0060 and p p =0.5465) carotid IMT values, when comparing patients with or without long-term Danazol prophylaxis. Conclusions Thickening of IMT due to Danazol use was not observed in HAE patients. We hypothesize that the functional deficiency of C1-INH might confer protection against atherosclerosis in these patients.
-
adverse effects of Danazol prophylaxis on the lipid profiles of patients with hereditary angioedema
The Journal of Allergy and Clinical Immunology, 2005Co-Authors: Gabor Szeplaki, Lilian Varga, Istvan Karadi, George Fust, Szilvia Valentin, Monika Kleiber, Laszlo RomicsAbstract:Background Hereditary angioedema (HAE) is a rare disorder caused by the deficiency of the C1-inhibitor gene (C1INH) . Patients experience recurrent bouts of edema, which can occur in almost any region of the body. As regards the treatment of the disease, Danazol (an attenuated androgen) is used, among other agents, for long-term prophylaxis. Objective The aim of this study was to investigate the possible adverse effects of Danazol on serum lipid profile, as well as to ascertain whether Danazol treatment is associated with an increased risk of atherosclerosis. Methods Serum concentrations of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, apolipoprotein A-I, apolipoprotein B-100, and lipoprotein(a) were compared between Danazol-treated patients with HAE and 2 control groups (ie, patients who did not receive long-term Danazol prophylaxis and untreated healthy subjects). Results Serum concentrations of HDL ( P =.0002 and P P =.0015 and P P =.0129 and P =.0127) and apolipoprotein B-100 ( P =.0456 and P =.0013) were higher in the Danazol-treated patients compared with the 2 control groups, respectively. No significant difference was found in total cholesterol, triglyceride, or lipoprotein(a) levels. Patients who received Danazol had an 11.6 (95% CI, 2.7-49.7) times higher risk for abnormally low HDL levels and a 4.4 (95% CI, 1.2-16.0) times lower risk for high LDL concentrations. Conclusions Our findings indicate that the long-term use of Danazol is associated with an increased risk for early atherosclerosis in patients with HAE. Consequently, monitoring of HDL and LDL levels at regular intervals is recommended during follow-up.
R J Caplan - One of the best experts on this subject based on the ideXlab platform.
-
zoladex goserelin acetate implant in the treatment of endometriosis a randomized comparison with Danazol the zoladex endometriosis study group
Obstetrics & Gynecology, 1993Co-Authors: John A Rock, J A Truglia, R J CaplanAbstract:OBJECTIVE To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and Danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study. METHODS Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or Danazol, 400 mg orally twice daily for 24 weeks. Efficacy was assessed by determination of pelvic signs and symptoms scores and revised AFS endometriosis scores. Endocrine effects were determined by measurements of hormone levels. Safety was evaluated by physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes. RESULTS Both treatments significantly (P < .0001) reduced mean subjective signs and symptoms scores both during and after therapy. The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53% for Zoladex and 33% for Danazol, and reduction in the endometrial implants score was 56% for Zoladex and 46% for Danazol. Serum estradiol levels decreased to the postmenopausal range in the Zoladex group and to the early follicular phase range in the Danazol group. Hypoestrogenic effects occurred more frequently with Zoladex, whereas androgenic side effects were more common with Danazol. There was a higher percentage of withdrawals due to adverse events with Danazol than with Zoladex. Mean bone mineral density decreased from baseline by 5.4% in the Zoladex group and increased by 1.0% in the Danazol group at the end of treatment. CONCLUSION Zoladex is as well tolerated and as effective as Danazol in the treatment of premenopausal women with endometriosis.
Kazutomo Akasofu - One of the best experts on this subject based on the ideXlab platform.
-
Adrenal Steroids in Serum during Danazol Therapy, Taking into Account Cross-Reactions between Danazol Metabolites and Serum Androgens.
Endocrine journal, 1993Co-Authors: Kouichi Murakami, Toshinobu Nakagawa, Yamashiro, Katsumi Araki, Kazutomo AkasofuAbstract:To investigate the changes in the serum androgen concentrations and the Free Androgen Index (FAT) in women during Danazol therapy, we measured the serum concentrations of adrenal steroids and Danazol metabolites, and then examined the effects of Danazol metabolites on assays for serum androgens. Thirteen women who had endometriosis were treated with Danazol (300 or 400 mg/day) for 8 to 16 weeks. Blood samples were taken before, during, and after the medication. During the Danazol therapy, serum testosterone (T), cortisol (F), and sex-hormone binding globulin (SHBG) significantly decreased (P
-
Levels of androgens and Danazol metabolites in serum during Danazol therapy.
Fertility and sterility, 1993Co-Authors: Kouichi Murakami, Toshinobu Nakagawa, Yamashiro, Katsumi Araki, Kazutomo AkasofuAbstract:Thirteen women who had endometriosis were treated with Danazol (300 to 400 mg/d). Levels of androgens and Danazol metabolites in serum and the influences of Danazol metabolites on the assays for serum androgen were investigated during Danazol therapy. Serum DHEAS significantly increased (P < 0.05), but serum DHEA slightly decreased. Serum T levels, measured by direct assay, were markedly elevated. However, measured after HPLC separation, the T levels in serum were significantly decreased (P < 0.05). There were considerable cross-reactions between Danazol metabolites and androgens (T, DHEA, and A) in RIA. Purification of androgens using column chromatography was necessary to measure serum androgens precisely.
John A Rock - One of the best experts on this subject based on the ideXlab platform.
-
zoladex goserelin acetate implant in the treatment of endometriosis a randomized comparison with Danazol the zoladex endometriosis study group
Obstetrics & Gynecology, 1993Co-Authors: John A Rock, J A Truglia, R J CaplanAbstract:OBJECTIVE To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and Danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study. METHODS Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or Danazol, 400 mg orally twice daily for 24 weeks. Efficacy was assessed by determination of pelvic signs and symptoms scores and revised AFS endometriosis scores. Endocrine effects were determined by measurements of hormone levels. Safety was evaluated by physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes. RESULTS Both treatments significantly (P < .0001) reduced mean subjective signs and symptoms scores both during and after therapy. The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53% for Zoladex and 33% for Danazol, and reduction in the endometrial implants score was 56% for Zoladex and 46% for Danazol. Serum estradiol levels decreased to the postmenopausal range in the Zoladex group and to the early follicular phase range in the Danazol group. Hypoestrogenic effects occurred more frequently with Zoladex, whereas androgenic side effects were more common with Danazol. There was a higher percentage of withdrawals due to adverse events with Danazol than with Zoladex. Mean bone mineral density decreased from baseline by 5.4% in the Zoladex group and increased by 1.0% in the Danazol group at the end of treatment. CONCLUSION Zoladex is as well tolerated and as effective as Danazol in the treatment of premenopausal women with endometriosis.
